[1]胡善联.2019年版世界卫生组织 基本药物目录的创新及特点[J].卫生经济研究,2019,(09):3-6.
　HU Shan-lian.Innovation and Characteristics of WHO Essential Medicines Model List 2019[J].Journal Press of Health Economics Research,2019,(09):3-6.
点击复制

2019年版世界卫生组织 基本药物目录的创新及特点
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2019年09期
页码:
3-6
栏目:
本刊特稿
出版日期:
2019-08-23

文章信息/Info

Title:
Innovation and Characteristics of WHO Essential Medicines Model List 2019
作者:
胡善联1
1.复旦大学公共卫生学院，上海 200032
Author(s):
HU Shan-lian
School of Public Health，Fudan University，Shanghai 200032，China
关键词:
基本药物目录; 世界卫生组织; 医疗保险药品报销目录; 药物经济学评价
Keywords:
essential medicines model list;  World Health Organization;  medical insurance drug reimbursement list;  pharmacoeconomic evaluation
分类号:
R19
文献标志码:
A
摘要:
通过对2019年版世界卫生组织基本药物目录的分析，重新认识基本药物的性质，在总结基本药物遴选原则和目录制定特点的基础上，提出对我国动态调整基本药物目录的启示：发挥药物经济学评价的作用、重视循证医学的证据、确保基本药物目录和医疗保险药品报销目录的衔接。
Abstract:
On the basis of the analysis of the WHO essential medicines model list in 2019，the nature of essential medicines has been re-recognized. Based on the summary of the principles of selecting essential medicines and the characteristics of list formulation，the enlightenment of dynamic adjustment of essential medicines list in China has been put forward，which plays a role of pharmacoeconomic evaluation and the importance to evidence-based medicine，and ensures the linkage between essential medicines list and medical insurance drug reimbursement list in the future.

参考文献/References:

[1] WHO：Model List of Essential Medicines. 21st List. 2019.
[2] WHO：WHO Policy Perspectives on Medicines. 4th The Selection of Essential Medicines.(M). June 2002.
[3] WHO: The Selection and Use of Essential Medicines. Report of the 22nd WHO Expert Committee on the 2019. Executive Summary.
[4] Seuba X: A Human Rights Approach to the WHO Model List of Essential Medicines. Bull WHO. 2006，84(5): 405-406.

相似文献/References:

[1]裴 婕,路 云,周 萍,等.瑞典基本药物目录的发展及启示[J].卫生经济研究,2018,(08):46.
　PEI Jie,LU Yun,ZHOU Ping,et al.The development and enlightenment of essential drug list in Sweden[J].Journal Press of Health Economics Research,2018,(09):46.
[2]李晓春,侯艳红.国家基本药物制度的完善及走向[J].卫生经济研究,2018,(12):34.
　LI Xiao-chun,HOU Yan-hong.The Improvement and Trend of the National Basic Drug System[J].Journal Press of Health Economics Research,2018,(09):34.
[3]任延峰,杨 毅,明 坚,等.药品集中采购政策的WHO经验及启示[J].卫生经济研究,2022,39(6):17.
　REN Yanfeng,YANG Yi,MING Jian,et al.Experience of WHO about Volume-Based Drug Procurement Policy[J].Journal Press of Health Economics Research,2022,39(09):17.

更新日期/Last Update: 2019-08-23